Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29261487 | 0.85 | LMNA (0.61) | LMNAALOX5L3MBTL1ALDH1A1TAS1R3 | |
| SCHEMBL13528632 | 0.84 | SMN1; SMN2 (0.57) | LMNAALOX5ALDH1A1HPGD | |
| SCHEMBL10315770 | 0.83 | L3MBTL1 (0.45) | LMNAALOX5L3MBTL1ALDH1A1TAS1R3 | |
| SCHEMBL20791688 | 0.80 | L3MBTL1 (0.53) | LMNAL3MBTL1ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL20791689 | 0.80 | L3MBTL1 (0.53) | LMNAL3MBTL1ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL2655264 | 0.79 | ACACB (0.54) | — | |
| SCHEMBL7723690 | 0.79 | ACACB (0.54) | — | |
| SCHEMBL7361907 | 0.77 | TDP1 (0.46) | LMNAALDH1A1TDP1MAPTALOX12 | |
| SCHEMBL31558936 | 0.77 | PDE2A (0.50) | LMNAALDH1A1 | |
| SCHEMBL14521516 | 0.77 | ACACB (0.49) | LMNAL3MBTL1TAS1R3TAS1R1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | LMNA 3235/4885ALOX5 1753/4885L3MBTL1 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.